Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

648
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
648
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

383
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
383
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

358
Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
358
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

1.0K
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
1.0K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

248
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
248
Measurement of Bioavailability: Pharmacokinetic Methods01:30

Measurement of Bioavailability: Pharmacokinetic Methods

517
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
517

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In-Depth Proteomic Quantification of Cell Secretome in Serum-Containing Conditioned Medium.

Analytical chemistry·2016
Same author

Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).

Leukemia research·2016
Same author

[Morphology and Spectral Properties Study of LaCeF3:Tb Microcrystalline].

Guang pu xue yu guang pu fen xi = Guang pu·2016
Same author

A highly selective fluorogenic probe for the detection and in vivo imaging of Cu/Zn superoxide dismutase.

Chemical communications (Cambridge, England)·2016
Same author

Development of a disaggregation-induced emission probe for the detection of RecA inteins from Mycobacterium tuberculosis.

Chemical communications (Cambridge, England)·2016
Same author

Bias-polarity-dependent resistance switching in W/SiO2/Pt and W/SiO2/Si/Pt structures.

Scientific reports·2016

Related Experiment Video

Updated: May 2, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

7.3K

Sensitivity-based analytical approaches to support human absolute bioavailability studies.

Xiaohui Sophia Xu1, Hao Jiang, Lisa J Christopher

  • 1Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543, USA.

Bioanalysis
|February 27, 2014
PubMed
Summary

Characterizing absolute bioavailability (BA) is crucial for drug development. This study explores using liquid chromatography-tandem mass spectrometry (LC-MS/MS) or accelerator mass spectrometry (AMS) for microdose studies to determine BA, aiding faster clinical development.

More Related Videos

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

12.7K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.8K

Related Experiment Videos

Last Updated: May 2, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

7.3K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

12.7K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.8K

Area of Science:

  • Pharmacokinetics and Drug Development
  • Analytical Chemistry in Pharmaceutical Research

Background:

  • Absolute bioavailability (BA) determination is vital for non-intravenous drug formulations.
  • Regulatory agencies accept co-administration of an intravenous (IV) isotopically labeled microdose with an oral therapeutic dose for human pharmacokinetic (PK) studies.
  • This approach accelerates clinical drug development.

Purpose of the Study:

  • To present a framework for selecting analytical methods in absolute BA studies.
  • To compare LC-MS/MS and AMS for quantifying microdoses in absolute BA determination.
  • To guide the choice between LC-MS/MS and AMS based on compound characteristics and required sensitivity.

Main Methods:

  • Discusses the use of Accelerator Mass Spectrometry (AMS) for radiolabeled microdoses.
  • Explores Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) for simultaneous quantification of labeled and unlabeled drugs.
  • Highlights the importance of lower limit of quantification (LLOQ) for method selection.

Main Results:

  • Both LC-MS/MS and AMS are viable for absolute BA studies.
  • LC-MS/MS offers cost-effectiveness due to simultaneous measurement of labeled and unlabeled analytes.
  • AMS provides a superior lower limit of quantification (LLOQ) for compounds with high volume of distribution or poor LC-MS/MS response.

Conclusions:

  • The choice between LC-MS/MS and AMS depends on the specific compound properties and sensitivity requirements.
  • Implementing microdose strategies with either LC-MS/MS or AMS can expedite clinical development.
  • A paradigm for selecting the appropriate analytical approach ensures efficient and accurate absolute BA data generation.